|
Corporate Contact:
Paul K. Wotton, Ph.D.
TOPIGEN Pharmaceuticals, Inc.
(514) 868-0404
paul.wotton@topigen.com
IR/PR Contact:
Martin A. Reynolds
LaVoie Group
(978) 745-4200 X107
mreynolds@lavoiegroup.com
FOR IMMEDIATE RELEASE:
TOPIGEN TO PROVIDE UPDATES ON NOVEL TREATMENTS FOR RESPIRATORY DISEASES AT CONFERENCES IN SCOTLAND AND CANADA
Presentations to Highlight Development Progress with Three Drug Candidates, as well as New Collaboration
Montreal, Canada, May 16, 2007 -- TOPIGEN Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specializing in respiratory diseases, today announced that
Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present updates on the company’s clinical programs at two upcoming conferences: BioEquity Europe 2007 and
Bio VentureForum East 2007.
At each of these conferences, Dr. Wotton will detail development progress on TOPIGEN’s small molecule and RNA-targeting product candidate programs, TPI ASM8 and TPI 1020, specifically the company’s successful steps in driving its product portfolio to its next stage of clinical development. Dr. Wotton will also provide details of a newly formed strategic collaboration with NOVAGALI Pharma S.A.
In July 2006, TOPIGEN announced that inhaled TPI ASM8 was the first drug of its kind to show pharmacological activity in the respiratory tract of patients with mild-to-moderate asthma. The study validated TOPIGEN’s proprietary multi-targeted therapeutic approach, demonstrating the drug candidate works effectively in the respiratory tract of patients with asthma, and its favorable safety
profile in this patient population. As a result, TPI ASM8 is currently being evaluated in an expanded Phase II study.
TPI 1020 is a novel corticosteroid that was in-licensed from NicOx S.A. (Eurolist: NICOX) and is part of an exciting new class of nitric oxide (NO)-donating therapies. TOPIGEN has recently conducted a dose escalating 21-day Phase II safety study in asthmatic smokers and will initiate a proof-of concept Phase II study in Chronic Obstructive Pulmonary Disease (COPD) later this year.
Dr. Wotton will be available for one-on-one meetings during the conferences.
Presentation Information
Dr. Wotton will present at BioEquity Europe 2007 (May 21-22, 2007) on May 22, 2007 at
2 p.m. (GMT) in Megalithic Room 2 at the Radisson SAS Hotel, Glasgow, Scotland
Dr. Wotton will speak at BIO VentureForum East 2007 (June 18-20, 2007) at the Marriott Chateau Champlain, Montreal, Quebec, Canada. Additional details will be available on TOPIGEN’s Website: www.topigen.com
About BioEquity Europe 2007
Eight years ago, BioCentury, EBD Group and BIO joined with like-minded collaborators in the international banking and venture communities to launch BioEquity Europe, a forum singularly focused on the financial health of European biotech. Building on its growing successes in Munich,
Frankfurt, Zurich, Paris, and Edinburgh, BioEquity Europe comes to Glasgow for its 8th anniversary
event, offering an unparalleled showcase of investment opportunities at a critical time in the history
of European life sciences. BioEquity Europe has established itself as the magnet for financial
dealmakers and the premier venue for life science companies positioning themselves to attract
capital from international investors. The challenge for investors, both specialists and
generalists, will be identifying top quality companies with forward momentum. In this setting,
BioEquity Europe 2007 convenes in Glasgow with a program uniquely designed to address the
desire of European money managers to invest on a global scale.
About Bio VentureForum East 2007
The Biotechnology Industry Organization (BIO), in partnership with 14 state biotechnology associations and BIOTECanada will bring venture capitalists together with promising seed, early-and late-stage private biotechnology product and platform companies from the East Coast. The conference will showcase up to 100 individual company presentations to leading North American venture capital firms in the life sciences field. Workshops and plenary sessions will be offered on trends in the biotech industry, with special focus on key success factors for early-stage companies, R&D, market trends, and financing. In addition, there will be formal and informal networking opportunities with industry CEOs and venture capital leaders.
About TOPIGEN
TOPIGEN is a privately-held, clinical-stage biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory diseases such as asthma, COPD and allergic rhinitis. TOPIGEN's pipeline includes small molecule and RNA-targeting therapeutics. The Company has two lead product candidates, inhaled TPI ASM8 for the treatment of asthma and inhaled TPI 1020 for the treatment of COPD, both currently undergoing Phase II trials. By topically targeting multiple affected airway receptors, the Company expects to improve outcomes for many patients with respiratory diseases. This specific approach has shown promising preclinical and clinical results in inhibiting the underlying inflammation associated with many pulmonary conditions. Current venture investors include CDP Capital - Technology Ventures, Desjardins Venture Capital, T2C2 / BIO, Fonds de solidarité FTQ, BDC Venture Capital and Multiple Capital Inc. For more detailed information on TOPIGEN visit www.topigen.com.
|
